SOBRsafe Inc. (NASDAQ: SOBR) announced that it has entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share. The transaction is expected to generate gross proceeds of approximately $3.1 million before fees and expenses. In conjunction with the warrant exercise, the company will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is anticipated to close on or about July 16, 2026.
The net proceeds from the transaction are designated for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. This capital injection provides SOBRsafe with additional financial flexibility to advance its alcohol detection technology and expand its market presence.
SOBRsafe specializes in next-generation alcohol detection technology that enables trust and empowers recovery through a human touch. The company's advanced transdermal (touch-based) technology detects and reports in real-time the presence of alcohol as emitted through a user's skin, eliminating the need for breath, blood, or urine samples. With a powerful backend data platform, SOBRsafe offers passive, dignified screening and monitoring solutions for behavioral health, family law, consumer markets, and licensing and integration applications.
This funding round underscores investor confidence in SOBRsafe's technology and business model. The company's innovative approach to alcohol monitoring addresses critical needs in various sectors, including behavioral health and legal compliance. By securing additional working capital, SOBRsafe is poised to enhance its product offerings and accelerate its growth trajectory.
For more details, the full press release is available at https://nnw.fm/jzJjF. Information about SOBRsafe can be found at www.sobrsafe.com.
